Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Rakovina Therapeutics Inc ( (TSE:RKV) ) is now available.
Rakovina Therapeutics Inc. and NanoPalm Ltd. have signed a Letter of Intent to form a joint venture aimed at co-developing novel small-molecule oncology therapeutics. This collaboration will combine Rakovina’s AI-enabled drug discovery platform with NanoPalm’s advanced lipid nanoparticle delivery technology, starting with the development of kt-3283, a dual PARP-HDAC inhibitor. The partnership represents NanoPalm’s strategic entry into oncology and aims to enhance the therapeutic index and delivery precision of cancer treatments, aligning with Saudi Arabia’s National Biotechnology Strategy. The joint venture will focus on advancing kt-3283 through preclinical and early clinical studies, with plans for global licensing and commercialization.
More about Rakovina Therapeutics Inc
Rakovina Therapeutics Inc. is a biopharmaceutical company focused on advancing cancer therapies through AI-powered drug discovery. The company is known for its innovative approach in developing oncology therapeutics, leveraging artificial intelligence to screen and predict drug-like characteristics. NanoPalm Ltd. is a biotechnology company based in Saudi Arabia, specializing in advanced lipid nanoparticle delivery systems, initially developed for gene therapy applications.
Average Trading Volume: 69,906
Technical Sentiment Signal: Sell
Current Market Cap: C$12.69M
See more data about RKV stock on TipRanks’ Stock Analysis page.